V WHO Package Leaflet - BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) - Grey Cap PDF
V WHO Package Leaflet - BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) - Orange Cap PDF
V WHO Package Leaflet - BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) - Purple Cap PDF
V WHO Package Leaflet - Janssen–Cilag International NV (Belgium) COVID-19 Vaccine (Ad26.COV2-S [recombinant]) PDF
V WHO Product Characteristics - BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) – Grey Cap PDF
V WHO Product Characteristics - BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) – Orange Cap PDF
V WHO Product Characteristics - BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) – Purple Cap PDF
V WHO Product Leaflet for Health Workers - Serum Institute of India Pvt Ltd - COVID-19 Vaccine (ChAdOx1-S [recombinant]) - COVISHIELD PDF
V WHO Recommendation for EUL of AZD1222 submitted by AstraZeneca AB and manufactured by SK Bioscience Co Ltd. (Published: 23 February 2021) PDF
V WHO Summary of Product Characteristics - BioNtech Tozinameran – COVID-19 mRNA vaccine (nucleoside modified) - Orange Cap PDF
V WHO Summary of Product Characteristics - Janssen–Cilag International NV (Belgium) COVID-19 Vaccine (Ad26.COV2-S [recombinant]) PDF
V WHO workshop on implementation of good manufacturing practices for biological products, Seoul, September 2018 PDF